Dan Lou
Direktor/Vorstandsmitglied bei China Medicinal Biotech Association
Profil
Dan Lou was the founder of Shenyang Sunshine Pharmaceuticals Co., Ltd.
founded in 1993 and 3SBio, Inc. founded in 1993 where he held the title of Executive Chairman from 2011 to 2012.
He currently holds a position as Executive Director at China Medicinal Biotech Association.
Mr. Lou received his undergraduate degree from Third Military Medical University in 1955.
Aktive Positionen von Dan Lou
| Unternehmen | Position | Beginn |
|---|---|---|
| China Medicinal Biotech Association | Direktor/Vorstandsmitglied | 18.10.2011 |
Ehemalige bekannte Positionen von Dan Lou
| Unternehmen | Position | Ende |
|---|---|---|
| 3SBIO INC. | Gründer | 01.04.2012 |
Shenyang Sunshine Pharmaceuticals Co., Ltd.
 Shenyang Sunshine Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Shenyang Sunshine Pharmaceutical Co., Ltd. engages in the development and production of biological products. It offers recombinant human erythropoietin, interferon alfa 2b, interleukin 2, and thrombopoietin injections. Its business activities include research and development, and manufacture of biochemical reagents, and pharmaceutical project investment advisory services. The company was founded on January 3, 1993 and is headquartered in Shenyang, China. | Gründer | - |
Ausbildung von Dan Lou
| Third Military Medical University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| 3SBIO INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| China Medicinal Biotech Association | |
Shenyang Sunshine Pharmaceuticals Co., Ltd.
Shenyang Sunshine Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Shenyang Sunshine Pharmaceutical Co., Ltd. engages in the development and production of biological products. It offers recombinant human erythropoietin, interferon alfa 2b, interleukin 2, and thrombopoietin injections. Its business activities include research and development, and manufacture of biochemical reagents, and pharmaceutical project investment advisory services. The company was founded on January 3, 1993 and is headquartered in Shenyang, China. | Health Technology |
